Abstract: The present invention provides a naphthalenetetracarboxylic acid diimide derivative represented by the following general formula (1): wherein R1 and R2, which are identical or different, each represent a substituted or non-substituted alkyl group or a substituted or non-substituted aromatic hydrocarbon group; R3 represents an alkyl group having 1 to 8 carbon atoms or an aromatic hydrocarbon group; R4, R5, R6 and R7, which are identical or different, each represent a hydrogen atom, a substituted or non-substituted alkyl group, or a substituted or non-substituted aromatic hydrocarbon group; and R1 and R2 may be linked to form a substituted or non-substituted heterocyclic group including a nitrogen atom; with compounds where all of R1, R2 and R3 are a methyl group, and compounds where both of R1 and R2 are a methyl group and R3 is a 1-octyl group being excluded.

Abstract: Present embodiments pertain to an improved electrostatographic imaging member having low contact friction surfaces to ease sliding mechanical interaction and suppressing abrasion/wear failure and methods of preparing thereof. The improved imaging member has layers comprising one or two low surface energy polymeric materials that enhance the physical and mechanical functions and reduce the layers surface contact friction of the imaging member to extend service life.

Abstract: A toner, a developer, a two-component developer, a developing device and an image forming apparatus are provided. In the image forming apparatus, images are formed with a developer that fills a developing tank of the developing device. The developer includes the toner containing at least a binder resin, a colorant, and a release agent, the release agent having an acid value of less than 4 mgKOH/g and in which an amount of the release agent exposed on a surface of toner is 0.5% by weight or more and 2.5% by weight or less of a total amount of the toner.

Abstract: The disclosure provides an electrophotographic toner and methods for preparing the electrographic toner. The electrographic toner includes a binder, a colorant and a releasing agent, wherein the electrophotographic toner includes strontium (Sr), iron (Fe), titanium (Ti), and silicon (Si) containing particles; wherein, if [Sr], [Fe], [Ti] and [Si] denote the intensities of Sr, Fe, Ti, and Si in the electrophotographic toner, respectively, as measured by X-ray fluorescence spectrometry, then the [Sr]/[Fe] ratio is in the range of about 5.0×10?1 to about 4.5, the [Ti]/[Fe] ratio is in the range of about 5.0×10?1 to about 8.1×10?1, and the [Si]/[Fe] ratio is in the range of about 2.0×10?3 to about 4.0×10?3.

Abstract: According to embodiments illustrated herein, there is provided a black toner having a resin, an optional additive, and at least two or more colored pigments, and the at least two or more colored pigments are selected from the group consisting of a blue pigment, a green pigment, a red pigment, a magenta pigment, a cyan pigment, a yellow pigment, a white pigment, and mixtures thereof, and the black toner has a colorimetric value L* of about less than 30.

Abstract: A toner for electrophotography includes toner particles containing at least a binder resin and a colorant, to which strontium titanate and hydrophobic silica as external additives are admixed, wherein the strontium titanate has a BET specific surface area of 20-50 m2/g and contains particles in a rectangular parallelepiped shape and wherein the hydrophobic silica contains hydrophobic silica A that has at least a BET specific surface area of 150-300 m2/g and the surface of which has been treated with an aminosilane and hexamethyldisilazane and hydrophobic silica B that has at least a BET specific surface area of 90-150 m2/g and the surface of which has been treated with hexamethyldisilazane.

Abstract: A method for printing a substrate by liquid developer electrography, the method comprising: (a) developing a latent image with liquid developer comprising toner particles dispersed in a carrier liquid, said toner particles comprising UV-curable additive; (b) transferring the developed image to the substrate; (c) at least partially fixing the image to the substrate; and (d) irradiating the at least partially fixed image with UV radiation to cure the UV-curable additive.

Abstract: Demands such as higher definition, higher opening aperture, and higher reliability on a full-color flat panel display have been increased. Such demands are big objects in advancing higher definition (increase in the number of pixels) of a light-emitting device and miniaturization of each display pixel pitch with reduction in size of the light-emitting device. An organic compound-containing layer is selectively deposited using a laser beam which passes through openings of a mask. An irradiated substrate provided with a light absorption layer and a material layer containing an organic compound and a deposition substrate provided with first electrodes are placed so as to face each other. The light absorption layer is heated by a laser beam which has passed through the openings of the mask, and the organic compound at a position overlapping with the heated region is vaporized, and accordingly the organic compound is selectively deposited over the deposition substrate.

Abstract: A polymer comprising a structural unit represented by the formula (I): wherein R1 represents a hydrogen atom or a methyl group, X represents a linear or branched chain C1-C6 alkylene group, Z represents a group represented by the formula (Ia): wherein R2 is independently in each occurrence a linear or branched chain C1-C6 alkyl group and m represents an integer of 0 to 15, and a structural unit represented by the formula (II): wherein R3 represents a hydrogen atom or a methyl group, R4 is independently in each occurrence a linear or branched chain C1-C6 alkyl group and n represents an integer of 0 to 4.

Abstract: A positive resist composition including a base material component (A) that exhibits increased solubility in an alkali developing solution under action of an acid; and an acid generator component (B) that generates an acid upon exposure, wherein the base material component (A) includes a polymeric compound (A1) having a structural unit (a10) derived from hydroxystyrene and a structural unit (a11) represented by general formula (a11-1) shown below: wherein R represents a hydrogen atom, an alkyl group of 1 to 5 carbon atoms, or a halogenated alkyl group of 1 to 5 carbon atoms; R21 represents an alkyl group; and R22 represents a group that forms an aliphatic monocyclic group of 7 to 10-membered ring together with the carbon atom to which this R22 group is bonded.

Abstract: A polymeric compound (A1) includes a structural unit (a0-1) represented by general formula (a0-1), a structural unit (a0-2) represented by general formula (a0-2), and a structural unit (a1-0-1) represented by general formula (a1-0-1), wherein relative to the combined total of all the structural units, the proportion of the structural unit (a0-1) is from 10 to 40 mol %, the proportion of the structural unit (a0-2) is from 5 to 20 mol %, and the proportion of the structural unit (a1-0-1) is from 10 to 55 mol %. [In the formulas, each of R1 and R independently represents a hydrogen atom, an alkyl group of 1 to 5 carbon atoms, or a halogenated alkyl group of 1 to 5 carbon atoms, R2, A and B each represents a divalent linking group, R3 represents a cyclic group containing —SO2— within the ring skeleton thereof, and R4 and X1 each represents an acid-dissociable, dissolution-inhibiting group.

Abstract: According to one embodiment, a storage medium comprises a transparent resin substrate on which a groove is formed, a recording layer formed on the groove on the transparent resin substrate, the recording layer using an organic dye material and recording information with a light beam of 620 nm or less in wavelength, a reflection layer formed on the recording layer, and a prevention layer formed between the recording layer and the reflection layer, the prevention layer preventing degradation of characteristics of the reflection layer.

Abstract: A method of making a lithographic printing plate includes the steps of a) providing a lithographic printing plate precursor including (i) a support having a hydrophilic surface or which is provided with a hydrophilic layer, (ii) a coating on the support including a photopolymerizable layer, and, optionally, an intermediate layer between the photopolymerizable layer and the support, b) image-wise exposing the coating in a plate setter, c) optionally, heating the precursor in a preheating unit, and d) developing the precursor off-press in a gumming unit by treating the coating of the precursor with a gum solution, thereby removing the non-exposed areas of the coating from the support, wherein the coating further includes a compound capable of interacting with the support, the compound being present in the photopolymerizable layer and/or in the intermediate layer.

Abstract: The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Abstract: Colloidal metal conjugates can be produced in high concentrations suitable for direct use, for example, in immunoassays. The colloidal metal conjugates can be used in devices for qualitative, semi-quantitative, or quantitative determination of the presence of compounds in samples, including biological samples.

Abstract: The present invention relates to the field of the distinction between bacterial meningitis and viral meningitis. It relates in particular to an in vitro method for detecting the presence of bacterial meningitis, which comprises determining the concentration of procalcitonin present in a test blood sample and of proteins present in a test cerebrospinal fluid sample, and comparing the concentrations thus determined to the concentration of procalcitonin and of proteins present in a reference sample or to a reference value. It also relates to a kit comprising means for detecting procalcitonin and proteins in the cerebrospinal fluid, and to the use thereof for the production of a diagnostic tool for bacterial meningitis.

Abstract: Reagents and compositions for use in reactions catalysed by luciferase enzymes, and in particular for use in luciferase-based gene reporter assays are described. The invention also provides methods and compositions for, inter alia, increasing the sensitivity and/or improving the kinetics of luciferase-catalysed reactions.

Abstract: Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line CmA40 as deposited under American Type Culture Collection patent deposit number PTA-11304 is produced by cell fusion of a parental cell and a myeloma cell line. The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line CmA40 as deposited under American Type Culture Collection patent deposit number PTA-11304 can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.

Abstract: A method for detecting small oligonucleotides includes providing a biological isolate containing at least one small oligonucleotide. The biological isolate may be contacted with at least one detection oligonucleotide having a label moiety and at least one bridge oligonucleotide under conditions such that the at least one small oligonucleotide and the at least one detection oligonucleotide are preferentially added to the bridge oligonucleotide to produce at least one labeled small oligonucleotide. At least one ligating reagent may be added to preferentially join the at least one small oligonucleotide and the at least one detection oligonucleotide. The at least one labeled small oligonucleotide may then be detected.

Abstract: Methods of using dyes and associated technology are provided. A dye, such as a monomeric dye or a dimeric dye, may be used in a nucleic acid gel staining application and/or a nucleic acid detection application. Such a dye and a salt that comprises an anion that is associated with a strong acid and a cation that is associated with a strong base may be used in such an application. A dimeric dye, such as a dimeric dye capable of forming a hairpin-like structure, may be used to stain and/or detect nucleic acids via a release-on-demand mechanism. A dimeric dye having low background fluorescence in the absence of nucleic acids and high fluorescence in the presence of nucleic acids, upon binding therewith, may be used to stain and/or detect nucleic acids.

Abstract: Primer sets for amplifying two genes (the CYP2C9 gene and the VKORC1 gene) by a gene amplification method are provided, wherein the primer sets can amplify respective target regions of the two genes specifically and efficiently in the same reaction system simultaneously. Two pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 5 and 29 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 18 and 38, respectively. The use of these primer sets makes it possible to specifically amplify target regions including sites where polymorphisms to be detected are generated in the CYP2C9 gene and the VKORC1 gene, in the same reaction solution simultaneously.

Abstract: In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. According to the present invention, Lrp4, a gene that is specifically expressed in dopaminergic neuron proliferative progenitor cells prior to cell cycle exit, was identified. The use of Lrp4 expression in cells as an index allows for the isolation. of cells suitable for transplantation therapy of neurodegenerative diseases such as Parkinson's disease in terms of safety, survival rate, and network formation ability.

Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Abstract: A method is provided for specifically detecting a G-quadruplex, and the like. The method is characterized by including the steps of preparing a solution including an anionic planar phthalocyanine and mixing the solution with a sample solution to obtain a liquid mixture. The solution includes an anionic planar phthalocyanine. The method also includes a step of measuring the absorbance at 640 to 740 nm of the obtained liquid mixture.

Abstract: Comparative genomic hybridization assays and compositions for use in practicing the same are provided. A characteristic of the subject comparative genomic hybridization assays is that solid support immobilized oligonucleotide feature elements, e.g., in the form of an array, are employed. Specifically, at least first and second nucleic acid populations prepared from genomic templates are contacted with a plurality of distinct oligonucleotide feature elements immobilized on a solid support surface and the binding of the at least first and second populations is then evaluated. Also provided are kits for use in practicing the subject methods.

Abstract: The invention provides methods and compositions for determining whether a subject is at risk of developing age-related macular degeneration, for example, the wet or neovascular form of age-related macular degeneration. The method involves determining whether the subject has a protective variant and/or a risk variant at a polymorphic site in the HTRA1 gene. In addition, the invention provides a method of treating or slowing the progression of age-related macular degeneration by reducing the expression of the HTRA1 gene, or reducing the biological activity of the HTRA1 gene product.

Abstract: Oligonucleotide sequences and methods for specifically detecting and differentiating amongst pathogenic E. coli in a complex sample. The complex sample can be a food sample, water sample, or selectively enriched food matrix. The methods of detection may utilize PCR amplification with, or without, an internal positive control, and appropriate primer pairs. Reagents for performing the methods can be supplied as a kit and/or in tablet form.

Abstract: Described are kits and methods useful for detection of respiratory pathogens (influenza A (including subtyping capability for H1, H3, H5 and H7 subtypes) influenza B, parainfluenza (type 2), respiratory syncytial virus, and adenovirus) in a sample. Genomic sequence information from the respiratory pathogens was analyzed to identify signature sequences, e.g., polynucleotide sequences useful for confirming the presence or absence of a pathogen in a sample. Primer and probe sets were designed and optimized for use in a PCR based, multiplexed Luminex assay to successfully identify the presence or absence of pathogens in a sample.

Abstract: A method for identifying A. baumannii with OXA-131-like drug resistance in diabetic patients includes the steps of obtaining a sample from a patient; identifying an isolate as A. baumannii; screening the isolate for genes encoding an OXA-51-like enzyme; sequencing any of the genes encoding an OXA-51-like enzyme; and identifying the isolate as OXA-131-like when the sequence matches the sequence for OXA-90 (SEQ ID NO: 1), OXA-130 (SEQ ID NO: 2), OXA-131 (SEQ ID NO: 3), or OXA-132 (SEQ ID NO: 4). The method may further include the step of identifying the ISAba1 sequence upstream from the gene encoding the OXA-131-like enzyme.

Abstract: In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.

Abstract: A method for examining an attachment or detachment of living cells, dead cells or cell-like particles on a surface using plasmon resonance includes irradiating a measurement region with beams over the entire angle of incidence spectrum and capturing, combining and evaluating beams with identical angles of incidence reflected from different points of the measurement region with a determination of the angle of light incidence with a lowest reflected light intensity and measuring an angle of incidence shift of an intensity minimum that occurs. The evaluating includes registering different angles of incidence of two or more intensity minima occurring simultaneously to reflect a respective level of the surface accumulations.

Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.

Abstract: The invention relates to an isolated or recombinant Na+/H+ exchanger comprising an isolated or recombinant Na+/H+ exchanger, particularly to the PBO-4 Na+/H+ exchanger. Also disclosed is an isolated or recombinant protein component of an H+-gated channel which can be affected by extracellular Ca2+ concentration. In particular, the invention relates to PBO-5 and/or PBO-8 and/or a H+-gated channel composed of PBO-5 and PBO-8. The invention relates to compounds isolated from a vertebrate organism, wherein said compounds comprise at least a part of a H+-gated channel or Na+/H+ exchanger. The invention also relates to a method for identifying a component of a H+-gated channel in a vertebrate organism.

Abstract: The invention relates to the detection and quantitation of cyclodextrins and cyclodextrin derivatives in solutions comprising a protein. The invention further relates to methods of evaluating pharmaceutical preparations for the presence of residual cyclodextrins.

Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 ?L or less of a legacy clinical sample.

Abstract: The present invention relates, e.g., to a method for pre-processing a sample for mass spectral analysis, comprising cleaving proteins in the sample to peptides and immunodepleting highly abundant and/or well-ionizing and/or proteotypic peptides from the sample. Also described are methods for identifying well-ionizing peptides for use in this and other methods; analytic (diagnostic) methods using antibodies against highly ionizable peptides from a protein target of interest; and compositions kits and devices comprising antibodies of the invention.

Abstract: Provided herein are, inter alia, methods for identifying a candidate compound for treating the toxic effects of compounds or molecules that bind to albumin in a subject. The methods include identifying test compounds that inhibit the binding between FcRn and albumin.

Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

Abstract: The present invention aims at developing a gene delivery system which has a high selectivity to a target cell and can introduce and express a gene with high efficiency, particularly developing such a system for use in a gene delivery therapy using a viral vector. The present invention provides a method for targeting a drug, which comprises the step of delivering a drug containing a therapeutic gene to a target site using an anti-PAP2a antibody.

Abstract: This invention relates to a gene encoding ?Np63? and screening methods of anticancer-drugs thereof, more specifically a gene encoding ?Np63? and a protein which is transported from nucleus to cytoplasm by contacting with potential anti-cancer-drugs in an epithelial cell carcinoma, a recombinant vector comprising said gene and reporter genes, and carcinoma cells comprising said vector. Also, This invention relates to high throughput screening methods of anticancer-drug comprising identifying the transportation of ?Np63? protein from nucleus to cytoplasm by contacting with potential anticancer-drug in a carcinoma cell.

Abstract: Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.

Abstract: Described are smoking cessation devices and kits for determining an advantageous time for a subject to quit smoking, and/or for extending the duration of smoking abstinence, based on serum levels of anti-nicotine antibodies. Related methods are also described.

Abstract: Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Abstract: The present invention relates to methods of measuring electrical properties of a cell using electrode devices comprising tapered nanotips having submicrometer dimensions (“nanoelectrodes”) for insertion into a cell. The devices are used to measure electrical properties of the cell and, optionally, may be used to electroporate, the cell or subcellular structures within the cell. The invention also provides arrays of electrode devices having nanotips for simultaneously or sequentially measuring the electrical properties of cells (e.g., such as surface immobilized cells). The electrodes can be used to measure properties of ion channels and in HTS assays to identify drugs which affect the properties of ion channels. The invention additionally provides microfluidic systems adapted for use with the electrode devices having nanotips. In combination with the electrodes, the microfluidic systems provide cell-based biosensors for monitoring cellular responses to conditions, such as exposure to candidate drugs.

Abstract: This invention relates to methods for rationally designing cell culture media for use in cell cultures, e.g., cell cultures employed in polypeptide production; cell culture media designed with the disclosed methods; methods of producing a polypeptide of interest, e.g., an antibody, using such media; polypeptides produced using the methods and media disclosed herein; and pharmaceuticals compositions containing such polypeptides. The rationally designed media contain a concentration of an amino acid that is calculated for use in cell mass, a concentration of the amino acid that is calculated for use in cell maintenance, and a concentration of the amino acid that is calculated for incorporation into the polypeptide of interest.

Abstract: The invention relates to novel neurogenin proteins, nucleic acids and antibodies.

Abstract: Ovarian germ-line-competent embryonic stem cells (GLC-ESC) are cultured, either in the presence or absence of a compound having estrogenic activity. The GLC-ESC are either collected prior to specific commitment or are permitted to remain in the culture medium for a time sufficient to develop into oocytes, and the oocytes may be fertilized by adding sperm to the culture medium. The fertilized oocytes may be permitted to develop into embryos, which may be transferred into the uterus of an adult human female or frozen for later use. The invention provides a method for obtaining by in vitro fertilization an embryo that is genetically related to a human female who is not producing oocytes.

Abstract: This invention provides for methods of sequencing and performing polymerase reactions using an improved generation of nucleic acid polymerases. The improvement is the fusion of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the processivity of the polymerase.

Abstract: After various sugar nucleotide solutions and glycosyltransferases (or primers) have been mixed, they are introduced into a reaction tank (column) with primers (or glycosyltransferases) immobilized thereon. Then solutions coming out of the reaction tank are led to an ultrafiltration column. The oligosaccharide synthesizer according to the present invention is equipped with a flow path for ensuring that glycosyltransferases or primers separated by the ultrafiltration column are returned into a container for storing each solution in a sample injector.

Abstract: Described herein are variants of H. jecorina CBH I, a Cel7 enzyme. The present invention provides novel cellobiohydrolases that have improved thermostability and reversibility.